A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 17.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...
We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...
Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 ...
Incyte’s Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback